Tissue-engineered recombinant human collagen-based corneal substitutes for implantation: Performance of type I versus type III collagen

Kimberley Merrett, Per Fagerholm, Christopher R. McLaughlin, Subhadra Dravida, Neil Lagali, Naoshi Shinozaki, Mitchell A. Watsky, Rejean Munger, Yasuhiro Kato, Fengfu Li, Christopher J. Marmo, May Griffith

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

PURPOSE. To compare the efficacies of recombinant human collagens types I and III as corneal substitutes for implantation. METHODS. Recombinant human collagen (13.7%) type I or III was thoroughly mixed with 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide. The final homogenous solution was either molded into sheets for in vitro studies or into implants with the appropriate corneal dimensions for transplantation into minipigs. Animals with implants were observed for up to 12 months after surgery. Clinical examinations of the cornea included detailed slit lamp biomicroscopy, in vivo confocal microscopy, and fundus examination. Histopathologic examinations were also performed on corneas harvested after 12 months. RESULTS. Both cross-linked recombinant collagens had refractive indices of 1.35, with optical clarity similar to that in human corneas. Their chemical and mechanical properties were similar, although RHC-III implants showed superior optical clarity. Implants into pig corneas over 12 months show comparably stable integration, with regeneration of corneal cells, tear film, and nerves. Optical clarity was also maintained in both implants, as evidenced by fundus examination. CONCLUSIONS. Both RHC-I and -III implants can be safely and stably integrated into host corneas. The simple cross-linking methodology and recombinant source of materials makes them potentially safe and effective future corneal matrix substitutes.

Original languageEnglish (US)
Pages (from-to)3887-3894
Number of pages8
JournalInvestigative Ophthalmology and Visual Science
Volume49
Issue number9
DOIs
StatePublished - Sep 1 2008

Fingerprint

Collagen Type III
Cornea
Collagen
Collagen Type I
Ethyldimethylaminopropyl Carbodiimide
Miniature Swine
Refractometry
Corneal Transplantation
Tears
Confocal Microscopy
Regeneration
Swine

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Tissue-engineered recombinant human collagen-based corneal substitutes for implantation : Performance of type I versus type III collagen. / Merrett, Kimberley; Fagerholm, Per; McLaughlin, Christopher R.; Dravida, Subhadra; Lagali, Neil; Shinozaki, Naoshi; Watsky, Mitchell A.; Munger, Rejean; Kato, Yasuhiro; Li, Fengfu; Marmo, Christopher J.; Griffith, May.

In: Investigative Ophthalmology and Visual Science, Vol. 49, No. 9, 01.09.2008, p. 3887-3894.

Research output: Contribution to journalArticle

Merrett, K, Fagerholm, P, McLaughlin, CR, Dravida, S, Lagali, N, Shinozaki, N, Watsky, MA, Munger, R, Kato, Y, Li, F, Marmo, CJ & Griffith, M 2008, 'Tissue-engineered recombinant human collagen-based corneal substitutes for implantation: Performance of type I versus type III collagen', Investigative Ophthalmology and Visual Science, vol. 49, no. 9, pp. 3887-3894. https://doi.org/10.1167/iovs.07-1348
Merrett, Kimberley ; Fagerholm, Per ; McLaughlin, Christopher R. ; Dravida, Subhadra ; Lagali, Neil ; Shinozaki, Naoshi ; Watsky, Mitchell A. ; Munger, Rejean ; Kato, Yasuhiro ; Li, Fengfu ; Marmo, Christopher J. ; Griffith, May. / Tissue-engineered recombinant human collagen-based corneal substitutes for implantation : Performance of type I versus type III collagen. In: Investigative Ophthalmology and Visual Science. 2008 ; Vol. 49, No. 9. pp. 3887-3894.
@article{1e546c3bebea4907b5842b1ee1180df5,
title = "Tissue-engineered recombinant human collagen-based corneal substitutes for implantation: Performance of type I versus type III collagen",
abstract = "PURPOSE. To compare the efficacies of recombinant human collagens types I and III as corneal substitutes for implantation. METHODS. Recombinant human collagen (13.7{\%}) type I or III was thoroughly mixed with 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide. The final homogenous solution was either molded into sheets for in vitro studies or into implants with the appropriate corneal dimensions for transplantation into minipigs. Animals with implants were observed for up to 12 months after surgery. Clinical examinations of the cornea included detailed slit lamp biomicroscopy, in vivo confocal microscopy, and fundus examination. Histopathologic examinations were also performed on corneas harvested after 12 months. RESULTS. Both cross-linked recombinant collagens had refractive indices of 1.35, with optical clarity similar to that in human corneas. Their chemical and mechanical properties were similar, although RHC-III implants showed superior optical clarity. Implants into pig corneas over 12 months show comparably stable integration, with regeneration of corneal cells, tear film, and nerves. Optical clarity was also maintained in both implants, as evidenced by fundus examination. CONCLUSIONS. Both RHC-I and -III implants can be safely and stably integrated into host corneas. The simple cross-linking methodology and recombinant source of materials makes them potentially safe and effective future corneal matrix substitutes.",
author = "Kimberley Merrett and Per Fagerholm and McLaughlin, {Christopher R.} and Subhadra Dravida and Neil Lagali and Naoshi Shinozaki and Watsky, {Mitchell A.} and Rejean Munger and Yasuhiro Kato and Fengfu Li and Marmo, {Christopher J.} and May Griffith",
year = "2008",
month = "9",
day = "1",
doi = "10.1167/iovs.07-1348",
language = "English (US)",
volume = "49",
pages = "3887--3894",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "9",

}

TY - JOUR

T1 - Tissue-engineered recombinant human collagen-based corneal substitutes for implantation

T2 - Performance of type I versus type III collagen

AU - Merrett, Kimberley

AU - Fagerholm, Per

AU - McLaughlin, Christopher R.

AU - Dravida, Subhadra

AU - Lagali, Neil

AU - Shinozaki, Naoshi

AU - Watsky, Mitchell A.

AU - Munger, Rejean

AU - Kato, Yasuhiro

AU - Li, Fengfu

AU - Marmo, Christopher J.

AU - Griffith, May

PY - 2008/9/1

Y1 - 2008/9/1

N2 - PURPOSE. To compare the efficacies of recombinant human collagens types I and III as corneal substitutes for implantation. METHODS. Recombinant human collagen (13.7%) type I or III was thoroughly mixed with 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide. The final homogenous solution was either molded into sheets for in vitro studies or into implants with the appropriate corneal dimensions for transplantation into minipigs. Animals with implants were observed for up to 12 months after surgery. Clinical examinations of the cornea included detailed slit lamp biomicroscopy, in vivo confocal microscopy, and fundus examination. Histopathologic examinations were also performed on corneas harvested after 12 months. RESULTS. Both cross-linked recombinant collagens had refractive indices of 1.35, with optical clarity similar to that in human corneas. Their chemical and mechanical properties were similar, although RHC-III implants showed superior optical clarity. Implants into pig corneas over 12 months show comparably stable integration, with regeneration of corneal cells, tear film, and nerves. Optical clarity was also maintained in both implants, as evidenced by fundus examination. CONCLUSIONS. Both RHC-I and -III implants can be safely and stably integrated into host corneas. The simple cross-linking methodology and recombinant source of materials makes them potentially safe and effective future corneal matrix substitutes.

AB - PURPOSE. To compare the efficacies of recombinant human collagens types I and III as corneal substitutes for implantation. METHODS. Recombinant human collagen (13.7%) type I or III was thoroughly mixed with 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide. The final homogenous solution was either molded into sheets for in vitro studies or into implants with the appropriate corneal dimensions for transplantation into minipigs. Animals with implants were observed for up to 12 months after surgery. Clinical examinations of the cornea included detailed slit lamp biomicroscopy, in vivo confocal microscopy, and fundus examination. Histopathologic examinations were also performed on corneas harvested after 12 months. RESULTS. Both cross-linked recombinant collagens had refractive indices of 1.35, with optical clarity similar to that in human corneas. Their chemical and mechanical properties were similar, although RHC-III implants showed superior optical clarity. Implants into pig corneas over 12 months show comparably stable integration, with regeneration of corneal cells, tear film, and nerves. Optical clarity was also maintained in both implants, as evidenced by fundus examination. CONCLUSIONS. Both RHC-I and -III implants can be safely and stably integrated into host corneas. The simple cross-linking methodology and recombinant source of materials makes them potentially safe and effective future corneal matrix substitutes.

UR - http://www.scopus.com/inward/record.url?scp=53149144307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149144307&partnerID=8YFLogxK

U2 - 10.1167/iovs.07-1348

DO - 10.1167/iovs.07-1348

M3 - Article

C2 - 18515574

AN - SCOPUS:53149144307

VL - 49

SP - 3887

EP - 3894

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 9

ER -